Determining Cell Markers for the Evaluation of HUVEC and HUVSMC Phenotypes on Formalin Fixed, Paraffin Embedded Blood Vessel Mimics by Miracle, Christopher Michael
  
 
Determining Cell Markers for the Evaluation of HUVEC and 
HUVSMC Phenotypes on Formalin Fixed, Paraffin Embedded 
Blood Vessel Mimics  
 
 
 
 
A Senior Project  
Presented to  
 
 
The Faculty of the Department of Biomedical Engineering 
California Polytechnic State University, San Luis Obispo 
 
 
In Partial Fulfillment  
of the Requirements for the Degree 
Bachelor of Science  
 
 
By  
 
 
Christopher Michael Miracle 
January, 2012  
Introduction 
Minimally invasive procedures have become the treatment of choice for many 
cardiovascular diseases, leading to a high demand for the development of new intravascular 
devices such as stents.  As a result, a great need exists for the preliminary assessment of tissue 
responses to these newly emerging stent designs and modifications, but set-up time and a lack of 
facilities and personnel limit animal studies.  A three-dimensional in-vitro testing system, or 
blood vessel mimic (BVM), has been developed, which allows for more efficient initial 
assessments to be performed on a large number of stent modifications to direct future animal and 
clinical studies toward only the most promising of these devices [1]. 
Current research focuses on developing BVMs that are both anatomically and 
physiologically representative of arterial blood vessels, as they are the focus of many 
cardiovascular treatments and therapies due to their propensity for disease.  Prior to discussing 
the current research, it is necessary to understand the structure and function of arteries which 
BVMs aim to mimic.  
The typical structure of normal arteries is comprised of three layers; intima, media, and 
adventitia [2].  The innermost layer, the intima, consists of a monolayer of endothelial cells (EC) 
known as the endothelium.  The endothelium, playing a physiological role, serves as an anti-
thrombogenic surface to minimize friction between the arterial wall and blood cells and prevent 
platelet aggregation [3].  It is also responsible for regulating the permeability of the vessel wall 
as well as the activity of arterial smooth muscle cells [3].   
The middle layer, consisting of elastin sheets and smooth muscle cells (SMC), is referred 
to as the media.  It plays both a structural as well as physiological role as it is responsible for the 
majority of the strength of the vessel as well as the regulation of circulatory dynamics [4].  As 
previously alluded to, smooth muscle cells of the media respond to growth factors that are 
excreted by the endothelial cells during both normal vessel repair as well as pathological 
pathways such as atherosclerosis and restenosis [3].  
The final, most superficial layer of the arterial vessel, or adventitia, consists mostly of 
fibroblasts.  This layer primarily plays a structural role as these cells produce collagen and elastic 
fibers, which protect and reinforce the vessel.  This layer helps maintain the vessel integrity and 
ultimately prevents the expansion of the vessel beyond its limit during the systolic, or high 
pressure period of the cardiovascular cycle [3].   
Now that the structure and function of arteries has been reviewed, it is necessary to 
discuss the initial BVM design and the direction of current and future research.  Preliminary 
BVMs were developed with the use of fat-derived human microvascular endothelial cells 
(HMVEC) sodded on an expanded polytetrafluoroethylene (ePTFE), tubular scaffold with the 
use of a perfusion bioreactor [1].  The resulting endothelial cell layer is intended to imitate the 
endothelium of the tunica intima and is critical in developing an in-vitro model of a native artery.   
In an effort to create a more physiologically representative model, research has focused 
on the use of large vessel endothelial cells, specifically human umbilical vein endothelial cells 
(HUVEC) rather than the previously mentioned HUMECs.  Similarly, a dual-sodding technique 
has been developed to introduce a second cell layer onto the construct using human umbilical 
vein smooth muscle cells (HUVSMC) [5].  This smooth muscle cell layer is intended to mimic 
the anatomical and physiological function of the tunica media as mentioned earlier.    
While research has focused on increasing the physiological accuracy of other components 
of the BVM system -- including scaffold material selection [6-8], the bioreactor system [9, 10], 
and more -- the remainder of this paper discusses the selection of cell markers and the initial 
development of staining protocols.  This is necessary to determine the effectiveness of the dual 
sodding technique as it pertains to maintaining the desired cellular phenotype of both HUVECs 
and HUVSMCs sodded onto an ePTFE scaffold to ensure the BVM remains physiologically 
accurate immediately following the cell-sodding procedure.   
 
Background 
 In order to discuss the criteria used to select the cell markers to detect both the desired 
HUVEC and HUVSMC phenotypes on the scaffold following the dual cell-sodding technique, it 
is necessary to review the antibody targets most commonly used to identify both endothelial and 
vascular smooth muscle cells. 
 
Vascular Endothelial Cells 
While there are dozens of cell markers used to identify vascular endothelial cells, both 
specific and non-specific to EC, the following discusses four of the more common cell markers 
used to identify vascular EC in normal and pathophysiologic tissue with an 
immunohistochemical technique, as found in the peer-reviewed literature.  These four cell 
markers include vonWillebrand Factor (vWF), intercellular adhesion molecule (ICAM-1 or 
CD54), platelet endothelial cell adhesion molecule (PECAM-1 or CD31), and vascular cell 
adhesion molecule (VCAM-1 or CD106).   
 vonWillebrand Factor is a highly multimeric glycoprotein secreted by vascular ECs with 
two separate biological functions -- the carrier for coagulation Factor VIII, an essential blood 
clotting factor, and as the cofactor required for platelets to bind to collagen exposed when the 
vessel wall is damaged [11].  These functions require the constitutive expression of vWF in 
endothelium (from Weibel-Palade bodies), megakaryocytes, and connective tissue [12].  The 
secretion of vWF from Weibel-Palade bodies of ECs is initiated by a very limited range of 
molecules, mainly thrombin and histamine [11].   
Thrombin is generated during the blood clotting process when prothrombin, secreted by 
the liver into the blood stream, is cleaved [2].  HUVECs, whether in culture or sodded onto a 
BVM, does not come into contact with blood at any point, and are therefore not expected to 
contact thrombin anywhere throughout the BVM system.  Histamine, a compound involved in 
local immune response, is mostly generated and secreted in the granules in mast cells or 
basophils [2], and similar to thrombin, is not expected to be present in the culture of HUVECs or 
the BVM system since mast cells and basophils are not present.  Since the two molecules largely 
responsible for the secretion of vWF from the Weibel-Palade bodies of ECs do not exist in the 
BVM system, vWF expression by HUVECs in the BVM system may be minimal, if it occurs at 
all.   
ICAM-1 is a transmembrane, cell-surface glycoprotein typically expressed in ECs as well 
as the cells of the immune system such as macrophages and lymphocytes [13].  ICAM-1 is 
present in very low concentrations in the membranes of EC, and its expression is only 
upregulated on cytokine activated endothelium [14].  ICAM-1 is most often involved in the 
promotion and binding of leukocytes to the endothelium during a local immune response [15].   
While staining ECs for ICAM-1 is common in the literature, it is often done in 
conjunction with an array of other adhesion molecules and performed when immune-mediated 
cell-cell adhesion reactions are of interest [16-19].  Since ICAM-1 is only continuously 
expressed at very low concentrations, rarely utilized on its own in peer-reviewed literature, not 
entirely specific to vascular EC, and typically involved in immune-mediated reactions, it may not 
be the optimal cell marker for identifying HUVECs in the BVM system. 
VCAM-1 is another cellular adhesion molecule that is only expressed on the surface of 
cytokine-activated endothelium in both large and small blood vessels [20] and, unlike ICAM-1, 
is restricted to the vascular tissue [21].  It promotes the adhesion of lymphocytes, monocytes, 
eosinophils, and basophils to the vascular endothelium.  It is also believed to play a role in the 
development of atherosclerosis and rheumatoid arthritis [20].   
 While the natural baseline concentrations of VCAM-1 in normal, non-pathological ECs 
of the endothelium may be undetermined, it is believed that the upregulation of VCAM is highly 
dependent on the presence of Tumor necrosis factor-alpha (TNF-α) and Interleukin-1 (IL-1) [21, 
22].  Since VCAM may only be expressed on cytokine-activated endothelium and its regulation 
may require the presence of specific factors and cytokines, its use for identifying HUVECs in the 
BVM system may not be ideal.  This is because TNF-α and IL-1 are not present in the BVM cell 
culture or BVM media and the degree of endothelium activation in the presence of the cell 
culture media used in the BVM system would need to be characterized prior to using antibodies 
for VCAM.  VCAM-1 expression has also been observed in other cell types, including vascular 
SMCs [23].  Since the antibody chosen to identify HUVECs in the BVM system will ultimately 
be used in the presence of HUVSMCs as well, VCAM-1 is not an ideal choice. 
 PECAM-1 is a single-membrane-spanning glycoprotein found on platelets, leukocytes, 
and endothelial cells [24].  With regards to EC, it is concentrated on cell-cell borders [11], has 
been shown to mediate cell-cell adhesion [25], and makes up a very large portion of the 
endothelial cell intercellular junction [26].  The minimal concentration of PECAM-1 at the EC 
junctions of the endothelium has been shown to be in the range of 10
6
 molecules [24].  In-situ, 
PECAM-1 is constitutively expressed on continuous endothelium of all blood vessel types [24] 
and is not expressed on fibroblasts or epithelial cells [27].  PECAM-1 has been used extensively 
as an immunostaining marker for identifying the ECs of blood vessels from a variety of species 
[24-28].  Similarly, PECAM-1 has been utilized as an EC cell marker for a variety of tissue 
engineering applications [29, 30], such as vascular grafts [31, 32], in which ECs are used, 
including the HUVEC cell line [29, 33, 34].   
 Due to the high concentration of PECAM-1 at EC junctions and its high specificity to 
vascular endothelial cells making up the endothelium of blood vessels, it may be an ideal cell 
marker for its use in identifying HUVECs in the BVM system, and its expression could be 
indicative of a physiologically accurate mimic of an endothelium on the scaffold.  Its extensive 
use in the literature for both natural tissue and engineered constructs has provided a large amount 
and variety of staining protocols that could serve as a starting point for developing a protocol 
suitable for the BVM system.  Lastly, its use with the specific HUVEC lineage that is used in the 
BVM lab ensures that successful results obtained in the past by other researchers could be 
duplicated.  Antibodies to PECAM-1 will be used in the remainder of this paper. 
 
Vascular Smooth Muscle Cells 
 While the literature identified many cell markers used to stain for the vascular endothelial 
cells of the endothelium in both pathological and non-pathological states, and though SMCs 
share many lineage-specific markers, only a small amount of markers were found to be 
commonly used for distinguishing vascular smooth muscle cells.  The most consistently used 
markers found were calponin, smooth muscle myosin heavy chain (SM-MHC) , SM22-α, and α-
smooth muscle actin (α-SMA).  The following discusses a brief background of each cell marker. 
 Calponin is a filament-associated protein that is involved in the regulation and 
modulation of smooth muscle contraction and is specific to smooth muscle tissue [35].  While 
calponin has been used extensively in the laboratory for identifying SMCs, a review of the 
literature will find that it is rarely, if at all, used on its own for staining SMCs, but rather with a 
cocktail of other SMC-specific markers such as SM22α, and α-SMA [36-38].  Also, the literature 
demonstrating the use of calponin has been associated with staining malignant tissue such as 
malignant myoepithelioma, a variety of carcinomas, and lesions.  Since calponin does not stand 
on its own as a SMC marker of normal smooth muscle tissue in the literature, it may not be ideal 
for identifying HUVSMCs of the BVM system. 
 Smooth muscle myosin heavy chain is a major contractile protein whose expression is 
believed to be exclusive to the SMC lineage [39] and highly prevalent toward the end of vascular 
smooth muscle cell differentiation [40].  It’s been used, most often in conjunction with α-SMA, 
to identify the smooth muscle tissue of vasculature, respiratory and gastrointestinal tracts, uterus, 
bladder, and eye [41].  Antibodies to SM-MHC have not been shown to cross-react with the 
myosin of skeletal muscle tissue [42].  Due to its extensive use in the literature, specificity to 
SMCs, and high prevalence in vascular SMCs, SM-MHC may be suitable for identifying 
HUVSMCs in the BVM system and should be considered for its use in the laboratory.   
 Upon first review, SM22-α, similar to SM-MHC, appeared to be a potential cell marker 
for the HUVSMCs in the BVM system, as it is commonly used to identify the SMCs in smooth 
muscle tissue.  However, upon further investigation, it was discovered that SM22-α is a 
calponin-related protein and it is expressed in conjunction with calponin [43].  It was also 
learned that SM22-α expression, though present during embryological development, is not 
upregulated in vascular smooth muscle tissue until adulthood [44].  Since the SMCs of the BVM 
system are isolated from umbilical vein blood, its concentration in HUVSMCs could be 
questionable.  SM22-α expression has also been discovered in cardiac and skeletal muscle cells 
[43].  Since SM22-α expression is associated with calponin, a cell marker that has already been 
determined to be non-ideal for its use in the BVM system, is not specific to only vascular smooth 
muscle cells, and concentrations are not increased until adulthood, it too should not be pursued 
for the BVM laboratory to identify HUVSMCs. 
 Alpha smooth muscle actin is a smooth-muscle specific intermediate-sized filament 
prevalent in vascular smooth muscle tissue [45].  While different smooth muscle cell types 
contain distinct and unique species of both contractile and cytoskeletal proteins, the greatest 
variation between cell types exists in these intermediate-sized filaments [46].  By taking 
advantage of this variation and the specificity of the intermediate-sized filaments to a given cell 
type, an intermediate filament, or a component of the filament, specific to vascular smooth 
muscle cells could be used as a cell marker to stain for the HUVSMCs in the BVM lab.   
It has been shown that the smooth muscle cells of the digestive, respiratory, and 
urogenital tract contain desmin and γ-type smooth muscle actin as the predominant and exclusive 
filaments; α-type smooth muscle actin is not expressed in these tissue types.  The intermediate 
filaments of vascular smooth cells differ in that they contain abundant amounts of vimentin and 
no desmin.  A component believed to be exclusive to vimentin filaments, and therefore specific 
to vascular smooth muscle cells, is α-smooth muscle actin [46].  Smooth muscle tissue of 
different blood vessels types such as aorta, small arteries, arterioles, venules, and the vena cava 
from a variety of species including human, bovine, porcine, and murine have all shown a high 
expression of α-SMA [46].  Its high specificity to only vascular SMCs of all types of blood 
vessels in a large variety of species suggests that α-SMA may serve as an ideal candidate for a 
cell marker toward HUVSMCs in the BVM lab and should be further investigated. 
Upon additional review, the reliability of α-SMA as a marker for staining vascular SMCs 
has been demonstrated and is extensively used in research.  Similar to the use of PECAM-1 in 
identifying EC in tissue-engineering applications, α-SMA is commonly used to stain for SMCs, 
including the HUVSMC lineage, in a variety of engineered vascular constructs as well [36, 47].  
Due to its specificity to vascular smooth muscle cells, reliability in previous research, and 
demonstrated use in staining for HUVSMCs in vascular tissue-engineering applications, 
antibodies toward α-SMA will be pursued for its use in the BVM lab. 
 
Procedure 
 Prior to developing an immunohistochemical staining protocol for detecting the 
expression of PECAM-1 by HUVECs and α-SMA by HUVSMCs on the ePTFE scaffold 
following the dual sodding method, it is necessary to determine if HUVECs and HUVSMCs 
express their respective cell markers when in culture in the first place.  After staining ECs and 
SMCs in culture for PECAM-1 and α-SMA, respectively, both positive and negative controls 
need to be established prior to using the antibodies for the IHC analysis of BVM samples. 
 
Cell Culture of HUVECs and HUVSMCs 
 Both cell types were thawed and incubated separately in their respective growth media in 
a 6-well plate overnight at 37⁰C and 5% CO2.  Prior to cell thawing and incubation, coverslips 
were placed on the bottom of each well so cells would grow on the coverslips rather than the 
surface of the wells.  This will allow for the easy transfer of coverslips to glass slides for the 
necessary microscopy after immunohistochemical staining.  HUVSMCs were thawed and 
incubated after their seventeenth passage while HUVECs were taken after having undergone 
nine passages.  Cell confluence was allowed to reach approximately 70-80% for both cell 
cultures prior to immunofluorescent staining.   
 
Immunofluorescent Staining of HUVECs and HUVSMCs in Culture 
 Following cell culture, both 6-well plates with each cell type was removed from the 
incubator and placed on the laboratory bench top for staining procedure. Media was aspirated 
and each well was lightly washed with PBS twice. Samples were then fixed with 5mL of 
Histochoice, per well, for 30 minutes. Samples were again washed twice with PBS then 
incubated for 20 minutes in 10% normal goat (Santa Cruz Biotechnology, sc-2043) and donkey 
(Santa Cruz Biotechnology, sc-2044) blocking serum, for SMCs and ECs, respectively.  All 
dilutions were made with PBS. Wells were washed twice with PBS, then samples were incubated 
for 60 minutes with a mouse monoclonal primary α-SMA antibody (Santa Cruz Biotechnology, 
sc-56499) for SMCs or a goat polyclonal primary PECAM antibody (Santa Cruz Biotechnology, 
sc-1506) for ECs, at a concentration of 1 ug/mL in 1% of their respective blocking serums.  To 
serve as negative controls, two wells per 6-well plate were incubated with PBS rather than the 
primary antibody solution.   
After the primary antibody incubations, samples were washed with three changes of PBS 
for five minutes each. All wells were then aspirated and incubated for 45 minutes with goat anti-
mouse (Santa Cruz Biotechnology, sc-2010) or donkey anti-goat (Santa Cruz Biotechnology, sc-
2024) fluorescein-conjugated secondary antibodies for the SMCs and ECs, respectively. 
Secondary antibody concentrations were 1 ug/mL with 1.5% normal blocking serum and 
incubation occurred with minimal light exposure. Cells were then washed three times in PBS for 
five minutes.  A 2 ug/mL concentration solution of Hoechst dye was prepared and 200 uL 
transferred to each well to stain nuclei. Cells were incubated for 15 minutes with the Hoechst dye 
and were then washed for five minutes, three times with PBS. PBS was aspirated and all 
coverslips with the stained cells were removed from the wells with a razor blade. Coverslips 
were transferred to glass slides, glued, and labeled accordingly. 
 
Fluorescent Microscopy 
 Slides were imaged using a wide-field fluorescent microscope.  Slides were viewed first 
under bright light to find an area of high cell density. This area was then exposed to light using a 
filter of excitation wavelength 365 nm and emission 480 nm for the Hoechst dye (nuclei) 
immediately followed by exposure using a filter of excitation wavelength 494 nm and emission 
518 nm for FITC, which shows the secondary antibody bound to α-SMA or PECAM, depending 
on the cell type. Using ImageCapturePro, the slides’ exposure to light was recorded for one 
second for Hoechst stain and ten seconds for FITC, to enable a more accurate representation of 
the total fluorescence. 
 
Image J Analysis 
 Images were processed using ImageJ by subtracting background and enhancing 
brightness and contrast for each image.  Corresponding images of Hoechst and FITC were then 
merged and a compiled image was generated showing both stained nuclei and α-SMA or 
PECAM-1 expression for HUVSMCs and HUVECs, respectively.   
 
IHC Analysis of Formalin Fixed, Paraffin Embedded Murine Tissue using PECAM-1 
 To generate both positive and negative controls for staining with the PECAM-1 primary 
antibody, an IHC protocol was performed on murine vascular tissue with and without the 
presence of the antibody, respectively.  An avidin-biotin complex (ABC) staining technique was 
used (Santa Cruz Biotechnology, sc- 2017).  Samples previously fixed in formalin and embedded 
in paraffin were prepared by sectioning a thickness of six microns, incubated in xylene to remove 
paraffin, and rehydrated with decreasing concentrations of ethanol.  All samples were incubated 
with 1.5% blocking serum for one hour.  Positive controls were incubated with the same primary 
antibody used during the fluorescent technique with concentrations ranging between 0.5 – 5.0 
ug/mL for 30 minutes, while negative controls were incubated in only PBS.  Then all samples 
were incubated with a 1 ug/mL concentration of biotinylated secondary antibody for 30 minutes 
and incubated with an avidin-biotin (AB) enzyme for an additional 30 minutes.  Finally, samples 
were incubated with a peroxidase substrate for one – ten minutes, dehydrated with increasing 
concentrations of ethanol, and washed in xylene prior to mounting with a coverslip.  All samples 
were washed with PBS three times for five minutes each between incubating in each reagent and 
an aspirating pump was used to remove PBS and reagents during the entire process.  After a 24-
hour drying period, samples were viewed and imaged using brightfield microscopy.  
Comparisons were made between positive and negative controls, and optimal concentrations of 
the primary antibody and peroxidase incubation times were determined for future use.   
 
IHC Analysis of Formalin Fixed, Paraffin Embedded Murine Tissue using α-SMA 
 The IHC procedure of murine vascular tissue using α-SMA to generate both negative and 
positive controls for the primary antibody were identical to those used with PECAM-1.  A mouse 
ABC staining kit (Santa Cruz Biotechnology, sc-2023) was used rather that the goat ABC kit use 
for PECAM, since the α-SMA primary antibody was a mouse monoclonal antibody.  Again, 
samples were incubated with and without the primary antibody.  Samples receiving the primary 
antibody (the same α-SMA primary antibody used during the immunofluorescent staining) used 
concentrations varying between 0.5 – 5.0 ug/mL and the peroxidase incubation period varied 
between one - ten minutes to determine the optimal parameters for future use.  Both controls 
were viewed and imaged using brightfield microscopy.   
 
Results 
Immunofluorescent staining of HUVECs and HUVSMCs in culture 
 Figure 1 corresponds to the immunofluorescent staining of HUVSMCs.  Figure 1A, taken 
at 100X magnification, is representative of the smooth muscles cells that were incubated without 
the presence of the α-SMA primary antibody to serve as negative controls.  The blue staining 
corresponds to the Hoechst dye used to identify nuclei and confirms the presence of cells.  
However, there is no green staining apparent throughout any of the entire sample.  
Figures 1B and 1C correspond to the positive controls in which HUVSMCs were stained 
with the α-SMA primary antibody with images taken at 100X and 400X magnification, 
respectively.  Again, the blue staining corresponds to cell nuclei and, unlike the negative 
controls, there is obvious green staining corresponding to the presence of α-SMA.  The merged 
image displays the smooth muscle actin in the cytoplasm surrounding the nuclei of each cell.   
 Figure 2 is representative of the immunofluorescent staining of HUVECs.  Results found 
with the EC staining were similar to the results obtained during the SMC staining.  Figure 2A 
corresponds to the negative controls in which EC were incubated without the PECAM-1 primary 
antibody.  The blue stain confirms the presence of cells.  There appears to be a small amount of 
light green staining as well, which is not expected when incubated without a primary antibody. 
There is a minimal presence and lack of intensity of this green staining.  Also, the merged image 
in the bottom of Figure 2A shows the presence of this green fluorescent where there are no cell 
nuclei (no blue staining).  Images shown for the negative controls were taken at 40X 
magnification.  However, the images obtained at 100X magnification show identical results as 
those represented in the figure. 
Figure 2B and 2C correspond to HUVECs stained with the PECAM-1 primary antibody 
serving as positive controls with images taken at 100X and 400X magnification, respectively.  
Figure 1: Immunofluorescent staining of HUVSMC in culture with α-SMA.  A) Negative control, HUVSMCs incubated 
without a primary antibody, demonstrates no false positives.  Images of HUVSMCs stained using the primary antibody to α-
SMA at B) 100X and C) 400X magnification show positive identification of HUVSMCs in culture expressing α-SMA  
Again, the blue staining of the cell nuclei confirm the presence of cells.  Unlike the negative 
controls, the green staining, representative of the presence of PECAM-1, is much more intense.  
When merged with the Hoechst stain, the green fluorescent surrounds the cell nuclei rather than 
randomly throughout the image, as was the case with the negative controls.   
 
IHC Analysis of Murine Vascular Tissue with PECAM-1 
 Figure 3 corresponds to the immunohistochemical staining of murine tissue fixed with 
formalin and embedded in paraffin.  The top and bottom images in Figure 3B, taken at 100X and 
400X magnitudes, respectively, correspond to the negative controls in which samples were 
Figure 2:  Immunofluorescent staining of HUVECs with PECAM-1 antibody.  A) Negative control, HUVECs incubated without 
a primary antibody, demonstrates no false positives.  Images of HUVECs stained using the primary antibody to PECAM-1 at 
B) 100X and C) 400X magnification show positive identification of HUVECs in culture expressing PECAM-1. 
incubated without the presence of PECAM-1 antibody.  There is no staining throughout any 
portion of the tissue, including the inner wall of the lumen where ECs should be present.  The 
images in Figure 3A correspond to the positive controls -- samples that were incubated with the 
PECAM-1 primary antibody.  The bottom image of Figure 3A, taken at 400X magnification, 
shows a very distinct staining of the endothelium of the tunica intima.  This correlates to a 
successful binding of PECAM-1 to the ECs of murine tissue and will serve as quality positive 
controls.   
 
Figure 3:  Immunohistochemical staining of formalin-fixed, paraffin-embedded murine tissue using PECAM-1.  A) Murine 
vascular tissue incubated in PECAM-1 antibody shows successful staining of the endothelial monolayer (images at 100X and 
400X mag.).  B) Negative control; identical murine tissue stained in the absence of the PECAM-1 antibody demonstrates no 
false positive staining.   
 IHC Analysis of Murine Vascular Tissue with α-SMA 
 Figure 4 corresponds to the immunohistochemical staining of formalin fixed murine 
tissue embedded in paraffin using the α-SMA antibody to detect the vascular SMC phenotype.  
Images in Figure 4B correspond to the negative controls in which the samples were not 
incubated with the primary antibody.  The top and bottom images of Figure 4B, taken at 100X 
and 400X magnification, respectively, show no staining throughout any of the tissue.  The 
images in Figure 4A are representative of the samples serving as positive controls in which the 
tissues were incubated in the presence of the α-SMA primary antibody.  Unlike the negative 
controls, there is a very distinct staining throughout the majority of the tissue, indicative of the 
Figure 4:  Immunohistochemical staining of formalin-fixed, paraffin-embedded murine tissue using a-SMA antibody.  A) 
Murine vascular tissue incubated in α-SMA antibody shows successful staining of the smooth muscle cells of the tunica 
media (images at 100X and 400X mag.).  B) Negative control; identical murine tissue stained in the absence of the α-SMA 
antibody demonstrates no false positive staining.   
presence of SMCs in the tunica media.  However, the staining that occurred is not nearly as dark 
as was found when staining the endothelium with PECAM-1.  This could be a concern and 
requires further investigation. 
 
Conclusion 
 The immunofluorescent staining of HUVSMCs in culture when incubated without the 
presence of the α-SMA primary antibody showed no staining throughout any of the samples.  
This is to be expected and confirms that the FITC-conjugated secondary antibody did not bind to 
the SMCs and that no false positives will be created when using the primary antibody.  When 
samples were incubated with the primary antibody, there was a distinct and intense presence of 
the green fluorescent surrounding the cell nuclei of each cell.  This confirms that the HUVSMCs 
express α-SMA when in culture prior to any cell-sodding process.  The α-SMA primary antibody 
can potentially be used for the IHC analysis in the BVM lab to determine whether or not 
HUVSMCs remain in the desired phenotype after the pressure-sodding technique used in the 
BVM lab. 
 While the results for the immunofluorescent staining of HUVECs in culture were similar 
to those of the HUVSMCs, the presence of green fluorescent in the negative controls could be a 
concern and require further discussion.  When comparing the green fluorescents between the 
negative and positive controls, there are several distinct differences which will be addressed. 
First, the green fluorescent of the negative controls is very dim and lacks the intensity of 
the positive controls.  Second, the minimal green fluorescent of the negative controls do not align 
with the cell nuclei and can be found throughout the glass slides where there are no cells.   
These two observations suggest that the green fluorescent of the negative controls are not 
indicative of the FITC-conjugated secondary antibody binding to the ECs without the primary 
antibody and that these are not false positives.  If the secondary antibody was binding to the ECs 
without the primary antibody, then the green staining would align at the same locations as the 
blue staining of the cell nuclei, which was not the case.  Rather, the very slight presence of dim 
green fluorescent is likely due to poor washing after the secondary antibody incubation period 
and that all of the non-bound secondary antibody was successfully removed in the washes prior 
to imaging.  This procedure should be attempted again, taking extra care to ensure that the PBS 
washes after the secondary antibody incubation period are performed diligently. 
The very high intensity of the green fluorescent in the positive controls, as well as its 
alignment with all EC nuclei suggests that HUVECs express PECAM-1 when in culture prior to 
any cell-sodding process and that the antibody can potentially be used for IHC analysis of 
HUVECs on BVMs. 
 The IHC analysis of murine vascular tissue with PECAM-1 successfully generated both 
positive and negative controls for the primary antibody to be used when analyzing HUVECs on 
the BVM.  The negative controls showed absolutely no staining throughout any of the tissue.  
This also confirms that, when using the proper protocol, no background or non-specific staining 
occurs.  The positive controls shows what a successful staining of EC on an inner lumen will 
look like and all that is required next is to optimize the protocol for staining in the presence of an 
ePTFE scaffold rather than the native tissue.  Complications include ensuring the scaffold 
remains adhered to glass slides during incubation periods and determining optimal primary 
antibody concentrations and peroxidase incubation periods as they will more than likely differ 
from results obtained with the murine tissue.   
 The IHC analysis of the murine vascular tissue with the α-SMA primary antibody used to 
identify the vascular SMCs successfully generated negative controls.  When incubated without 
the primary antibody, there is no staining throughout any of the tissue.  This confirms that the 
secondary antibody did not bind anywhere in the tissue and that no background or non-specific 
staining occurred.  While the positive controls differed significantly from the negative controls, 
the nature of the staining could be a concern. 
Rather than the darker brown staining common with a peroxidase technique, and shown 
in the PECAM-1 positive controls, the staining that occurred with α-SMA is a lighter red tint, 
even at the highest antibody concentrations and longest peroxidase incubation periods.  These 
results could not be a consequence of secondary antibody cross-reactivity, otherwise the negative 
and positive controls would be identical and the staining, if anything, would be expected to be 
even darker than those obtained when staining the endothelium with PECAM-1.  The same is 
true of primary antibody cross-reactivity, plus the staining occurs only in the location where 
SMCs are expected to reside.  If primary antibody cross-reactivity was occurring, we would 
expect to see staining throughout the entire tissue, not just concentrated in the tunica media.  
Endogenous biotin activity could not be the factor either because, again, the negative and 
positive controls would look identical. 
The lighter staining that occurs with the positive controls using α-SMA is likely a result 
of poor enzyme activity or primary antibody potency.  It should be noted that one vial of the 
primary antibody was handled poorly at some point during the shipping process from the vendor 
and that a fresh vial of α-SMA antibody could result in better staining.  If the problem persists, a 
higher concentration of the primary antibody exceeding 5.0 ug/mL and/or a peroxidase 
incubation period greater than ten minutes could be attempted.  Another suggestion would be to 
use an α-SMA primary antibody that was raised in a different species and would also require a 
different ABC staining kit, utilizing a different secondary antibody as well.  This is preferred 
over using higher concentrations of the current antibody, as the reagents are expensive and need 
to be used sparingly.  Another suggestion would be to use antibodies toward smooth muscle 
myosin heavy chain rather than the α-SMA primary antibody. 
While these suggestions may generate better positive controls, they may not be necessary 
when staining HUVSMCs on an ePTFE scaffold for several reasons.  First, the SMCs in the 
BVM system are human rather than murine.  This could provide different results than those of 
the murine tissue that was used for the controls, so the current mouse antibody may still work 
well with BVMs.  Second, there would not be a presence of a large variety of tissue types found 
in the murine samples (such as different types of connective tissue) as the BVM would consist of 
only the HUVSMCs, HUVECs, and the polymer scaffold.  So, if the large presence of other 
tissue types in the sample was a source of the problem, this would not occur with the BVM.  
Lastly, the sodding density of HUVSMCs onto the BVM, and the sum of any cell division that 
may occur immediately afterword is likely to be less than the total density of SMCs in the 
murine tissue.  So, if the problem with the α-SMA on the positive controls was that the primary 
antibody concentrations were too low, not very potent, or that the peroxidase enzyme was acting 
weakly, this might not be a concern when staining BVMs because there would be higher primary 
antibody-to-cell and peroxidase-to-AB enzyme ratios.  However, prior to optimizing the α-SMA 
protocol for analyzing HUVSMCs in the BVM system, these problems with the positive controls 
should be identified and addressed.   
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